Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC

Benjamin H. Lowentritt, MD, FACS, of Chesapeake Urology, sheds light on a real-world comparison of PSA response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide versus enzalutamide.

The study showed that a greater percentage of patients with de novo mCSPC treated with apalutamide achieved a deep, early PSA response by 6 months compared with those treated with enzalutamide.